{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-130093","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.419414+00:00","generated_at":"2026-06-07T06:14:45.935657+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents STAR-T trial misses primary effectiveness endpoint in overall population; positive trend in CABG subgroup","bullets":["STAR-T trial did not meet primary composite effectiveness endpoint in overall 140-patient population.","Safety endpoint met; DSMB found no safety issues with DrugSorb-ATR device.","In isolated CABG subgroup (over 90% of patients), reduced bleeding complications observed, including serious events.","Company expects to complete full data analysis in weeks and may submit to FDA/Health Canada.","Full results to be presented at ACC 2024 in Atlanta next April if accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-130093","json":"https://secwatch.observer/filing/0001104659-23-130093.json","markdown":"https://secwatch.observer/filing/0001104659-23-130093.md","text":"https://secwatch.observer/filing/0001104659-23-130093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923130093/0001104659-23-130093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923130093/tm2333824d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:14:45.935657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}